Secondary analysis of a phase 3 trial in 408 adults with uncontrolled CRSwNP: tezepelumab vs placebo improved smell scores (NPSD, UPSIT, SNOT-22) from week 4 to 52; anosmia at week 52 was 31.5% vs 75.8%.
Secondary analysisn = 408
Mullol et al. Early and Sustained Improvements in Sense of Smell With Tezepelumab Treatment in Patients With Chronic Rhinosinusitis With Nasal Polyps (WAYPOINT)